FDA Urges Analysis of Covariance for Randomized Control Trials

Drug Industry Daily
Drug sponsors can use complicated covariance analyses to help determine statistical significances or to help sharpen estimates of how well a treatment might work but they shouldn’t apply those analyses to anything in a clinical trial that might be affected by treatment, the FDA says in a new draft guidance document issued Wednesday.

To View This Article:


Subscribe To Drug Industry Daily